Evotec 566480, wohin geht die Reise??? (Seite 5711)
eröffnet am 12.01.07 11:23:52 von
neuester Beitrag 06.05.24 21:04:14 von
neuester Beitrag 06.05.24 21:04:14 von
Beiträge: 82.061
ID: 1.104.790
ID: 1.104.790
Aufrufe heute: 38
Gesamt: 16.217.362
Gesamt: 16.217.362
Aktive User: 0
ISIN: DE0005664809 · WKN: 566480
9,6250
EUR
-1,91 %
-0,1875 EUR
Letzter Kurs 06.05.24 Lang & Schwarz
Neuigkeiten
| Evotec Aktien jetzt im kostenlosen Demokonto handeln!Anzeige |
06.05.24 · Shareribs Anzeige |
06.05.24 · wO Newsflash |
06.05.24 · dpa-AFX Analysen |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 6.300,00 | +4.940,00 | |
| 1,4500 | +27,19 | |
| 1,6400 | +23,31 | |
| 1,3000 | +22,64 | |
| 2,7600 | +20,00 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7603 | -13,61 | |
| 7,8900 | -13,77 | |
| 8,6500 | -14,82 | |
| 7,5000 | -18,30 | |
| 23,140 | -19,90 |
Beitrag zu dieser Diskussion schreiben
Feedback
ukraine steht noch
russland is zu hause geblieben
evotec wird weiter gedeckelt
kaum handel
kurs langsam nach unten
gute nachrichten werden nicht wahrgenommen
armes evotec
russland is zu hause geblieben
evotec wird weiter gedeckelt
kaum handel
kurs langsam nach unten
gute nachrichten werden nicht wahrgenommen
armes evotec
PR Newswire
OXFORD England April 28 2014
OXFORD England April 28 2014 /PRNewswire-USNewswire/ -- Orca Pharmaceuticals a biotechnology start-up developing RORgamma inhibitors for the treatment of autoimmune diseases has announced a further investment of $1.3 million from BioMotiv a drug development accelerator based in Cleveland Ohio and affiliated with The Harrington Project.Founded in 2013 the company's technology is based on intellectual property developed in the laboratory of Professor Dan Littman of New York University a world leader in Th17 cell immunology.Orca also has close ties with Oxford University immunologists who are playing a key role in identifying promising therapeutic indications and selecting an optimised development candidate.
"This additional funding endorses the strength of the Orca program and provides resources for the advancement of a development candidate" said Roy Pettipher PhD founder and Chief Scientific Officer of Orca Pharmaceuticals.
Orca Pharmaceuticals is developing an oral drug to treat a range of autoimmune diseases with psoriasis as the primary therapeutic target. Working with Evotec AG the company has developed a series of potent and selective compounds with pharmaceutical properties that are amenable to clinical development. The additional investment will enable the company to select a clinical candidate optimised for activity on key pathogenic immune cells.
"The powerful combination of high quality medicinal chemistry target structure analysis and leading edge biological screening has enabled Orca to obtain potentially best-in-class RORgamma inhibitors targeting a variety of immune diseases" said David C. U'Prichard PhD Board Chairman of Orca Pharmaceuticals and Chief Scientific Officer of BioMotiv.
Mick Hunter PhD CEO of Orca Pharmaceuticals indicated that the company is now exploring additional development partnerships with pharmaceutical companies.
ContactOrca Pharmaceuticals LtdRoy Pettipher+44 (0) 1235 841542 rpettipher@orcaph.com
About Orca Pharmaceuticals
Orca Pharmaceuticals is a biopharmaceutical company focused on the discovery development and commercialization via partnership of targeted small molecule RORgamma inhibitor drugs to treat patients with autoimmune disease.For more information please visit: http://www.orcapharmaceuticals.com
About BioMotiv
BioMotiv is the mission-driven accelerator associated with The Harrington Project for Discovery & Development a $250 million national initiative for advancing medicine centered at University Hospitals of Cleveland.The focus is to accelerate breakthrough discoveries from research institutions into therapeutics for patients through an innovative model that efficiently aligns capital and collaborations.The company leverages an experienced team and advisory board to select fund and actively manage and advance a portfolio of programs.Products are advanced to clinical proof-of-concept and then partnered. Bio
More: http://www.pharmiweb.com/PressReleases/pressrel.asp?ROW_ID=8…
OXFORD England April 28 2014
OXFORD England April 28 2014 /PRNewswire-USNewswire/ -- Orca Pharmaceuticals a biotechnology start-up developing RORgamma inhibitors for the treatment of autoimmune diseases has announced a further investment of $1.3 million from BioMotiv a drug development accelerator based in Cleveland Ohio and affiliated with The Harrington Project.Founded in 2013 the company's technology is based on intellectual property developed in the laboratory of Professor Dan Littman of New York University a world leader in Th17 cell immunology.Orca also has close ties with Oxford University immunologists who are playing a key role in identifying promising therapeutic indications and selecting an optimised development candidate.
"This additional funding endorses the strength of the Orca program and provides resources for the advancement of a development candidate" said Roy Pettipher PhD founder and Chief Scientific Officer of Orca Pharmaceuticals.
Orca Pharmaceuticals is developing an oral drug to treat a range of autoimmune diseases with psoriasis as the primary therapeutic target. Working with Evotec AG the company has developed a series of potent and selective compounds with pharmaceutical properties that are amenable to clinical development. The additional investment will enable the company to select a clinical candidate optimised for activity on key pathogenic immune cells.
"The powerful combination of high quality medicinal chemistry target structure analysis and leading edge biological screening has enabled Orca to obtain potentially best-in-class RORgamma inhibitors targeting a variety of immune diseases" said David C. U'Prichard PhD Board Chairman of Orca Pharmaceuticals and Chief Scientific Officer of BioMotiv.
Mick Hunter PhD CEO of Orca Pharmaceuticals indicated that the company is now exploring additional development partnerships with pharmaceutical companies.
ContactOrca Pharmaceuticals LtdRoy Pettipher+44 (0) 1235 841542 rpettipher@orcaph.com
About Orca Pharmaceuticals
Orca Pharmaceuticals is a biopharmaceutical company focused on the discovery development and commercialization via partnership of targeted small molecule RORgamma inhibitor drugs to treat patients with autoimmune disease.For more information please visit: http://www.orcapharmaceuticals.com
About BioMotiv
BioMotiv is the mission-driven accelerator associated with The Harrington Project for Discovery & Development a $250 million national initiative for advancing medicine centered at University Hospitals of Cleveland.The focus is to accelerate breakthrough discoveries from research institutions into therapeutics for patients through an innovative model that efficiently aligns capital and collaborations.The company leverages an experienced team and advisory board to select fund and actively manage and advance a portfolio of programs.Products are advanced to clinical proof-of-concept and then partnered. Bio
More: http://www.pharmiweb.com/PressReleases/pressrel.asp?ROW_ID=8…
!
Dieser Beitrag wurde von MODernist moderiert. Grund: themenfremder Inhalt
Wollte mich auch schon drüber aufregen, aber sie fängt sich ja bereits wieder im RT 
=> Bei den niedrigen Umsätzen sowie dem Umfeld lohnt es nicht sich über +/- 10 Cents Volatilität Gedanken zu machen ...
=> Bei den niedrigen Umsätzen sowie dem Umfeld lohnt es nicht sich über +/- 10 Cents Volatilität Gedanken zu machen ...
Oje, der Kurs sieht hier ja wieder richtig mies aus. Irgendwie ist hier der Wurm drin.
Trading Spotlight
Antwort auf Beitrag Nr.: 46.878.812 von belliora am 26.04.14 10:38:48moin,
manchmal verliert man das ziel aus den Augen warte es bis zum Jahresende mal ab.
und bis dahin ein kl. wenig Lektüre für das erreichen persönlicher Ziele ( ich jammere auch nicht keiner hier, du bist der einzige )
http://evotec.sissy.bgcc.at/uploads/media_library/10/2014-04…
gruss
manchmal verliert man das ziel aus den Augen warte es bis zum Jahresende mal ab.
und bis dahin ein kl. wenig Lektüre für das erreichen persönlicher Ziele ( ich jammere auch nicht keiner hier, du bist der einzige )
http://evotec.sissy.bgcc.at/uploads/media_library/10/2014-04…
gruss
Antwort auf Beitrag Nr.: 46.874.070 von depulep am 25.04.14 12:14:50Bin nicht der einzige, der hier "rumheult"....aber einer muss ja den verdeckten Frust der investierten Poster voll abbekommen.
Wer sooo fest an Evotec glaubt, der hält das doch aus, oder?
Biotechs in USA am Freitag wieder massiv unter Druck, das dazu!
Wer sooo fest an Evotec glaubt, der hält das doch aus, oder?
Biotechs in USA am Freitag wieder massiv unter Druck, das dazu!
Antwort auf Beitrag Nr.: 46.874.070 von depulep am 25.04.14 12:14:50Mit sehr geringen Umsätzen wurde der Kurs heute um 3 Prozent gedrückt ...
wo ist die gegenbewegung
vorige woche grundlos nach unten gedrückt
trotz guter nachrichten bewegt sich nix
wann kommt der erste aujf die Q zahlen zu sprechen
keine meilensteine in1Q wie schlecht fallen die zahlen wohl aus
Paaaaanik
vorige woche grundlos nach unten gedrückt
trotz guter nachrichten bewegt sich nix
wann kommt der erste aujf die Q zahlen zu sprechen
keine meilensteine in1Q wie schlecht fallen die zahlen wohl aus
Paaaaanik
läuft ja wieder rund heute
Durchsuchen
06.05.24 · wO Newsflash · Amgen |
05.05.24 · wO Chartvergleich · Apple |
04.05.24 · wO Chartvergleich · American Express |
03.05.24 · EQS Group AG · Evotec |
02.05.24 · wO Newsflash · Honeywell International |
| Zeit | Titel |
|---|---|
| 03.05.24 | |
| 13.02.24 | |
| 22.01.24 | |
| 17.01.24 | |
| 08.01.24 | |
| 15.05.23 |